{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T04:37:13Z","timestamp":1787459833010,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In colorectal cancer (CRC)-related carcinomatosis, the risk of ovarian metastases (OM) is not well described, and practices during cytoreductive surgery (CRS) vary widely. Defining this risk is critical for counseling patients on the necessity of oophorectomy during CRS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study analyzed female patients with CRC-related carcinomatosis undergoing curative intent CRS with or without hyperthermic intraperitoneal chemotherapy (HIPEC) at a single center (2008\u20132024).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study identified 74 patients, 66% of whom were post-menopausal. The median Peritoneal Cancer Index (PCI) was 8 (interquartile range [IQR], 6\u201310), and all the patients had a complete cytoreduction (CCR 0\/1). Right-sided primary tumors were the most common (57%), and the histology was most commonly non-mucinous (\n                      <jats:italic>n<\/jats:italic>\n                      = 51, 69%), moderately differentiated (\n                      <jats:italic>n<\/jats:italic>\n                      = 49, 66%), and microsatellite stable (\n                      <jats:italic>n<\/jats:italic>\n                      = 67, 90%). Neoadjuvant therapy was common (\n                      <jats:italic>n<\/jats:italic>\n                      = 58, 78%), and 25 (34%) of the patients underwent HIPEC. Four of the patients (5%) had undergone bilateral salpingo-oophorectomy (BSO) before the diagnosis of peritoneal disease. Of the 70 remaining patients, 51 (73%) had grossly abnormal-appearing ovaries. Of the 70 patients, 65 (93%) had a bilateral or completion salpingo-oophorectomy, and 2 (3%) underwent a unilateral oophorectomy. Overall, 55 (79%) of the patients had pathologically confirmed OM. Of the 16 patients with normal-appearing ovaries who underwent oophorectomy, 4 (25%) had microscopic OM. Two (40%) of the five patients with normal-appearing ovaries preserved during CRS experienced ovarian recurrence within 15\u00a0months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Most of the female patients undergoing CRS for CRC-related carcinomatosis had OM, including 25% of the patients with normal-appearing ovaries. Short-interval recurrence was observed with ovarian preservation. Routine BSO should be strongly considered for patients undergoing CRS with curative intent.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-20254-7","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:06:44Z","timestamp":1784225204000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk of Ovarian Metastasis in Colorectal Cancer-Related Carcinomatosis"],"prefix":"10.1245","author":[{"given":"Ryan B.","family":"Morgan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Neilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Keeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LaDonna","family":"Kearse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kilian","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Delisle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Ochiai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Helmink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Paul","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria S.","family":"Higbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarett","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasey","family":"Matura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Sadasivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. Nancy","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Bednarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy","family":"Behman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Messick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Guraieb-Trueba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagan","family":"Ramamurthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Rodriguez-Bigas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Joshua","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Marincola Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"20254_CR1","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1002\/bjs.7196","volume":"97","author":"J Segelman","year":"2010","unstructured":"Segelman J, Fl\u00f6ter-R\u00e5destad A, Hellborg H, Sj\u00f6vall A, Martling A. Epidemiology and prognosis of ovarian metastases in colorectal cancer. Br J Surg. 2010;97:1704\u20139.","journal-title":"Br J Surg."},{"key":"20254_CR2","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/1471-2407-12-278","volume":"12","author":"W Li","year":"2012","unstructured":"Li W, Wang H, Wang J, Lv F, Zhu X, Wang Z. Ovarian metastases resection from extragenital primary sites: outcome and prognostic factor analysis of 147 patients. BMC Cancer. 2012;12:278.","journal-title":"BMC Cancer."},{"key":"20254_CR3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/bjs.7303","volume":"98","author":"DJ Evers","year":"2011","unstructured":"Evers DJ, Verwaal VJ. Indication for oophorectomy during cytoreduction for intraperitoneal metastatic spread of colorectal or appendiceal origin. Br J Surg. 2011;98:287\u201392.","journal-title":"Br J Surg."},{"key":"20254_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1245\/s10434-012-2623-9","volume":"20","author":"C Eveno","year":"2013","unstructured":"Eveno C, Go\u00e9r\u00e9 D, Dartigues P, et al. Ovarian metastasis is associated with retroperitoneal lymph node relapses in women treated for colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2013;20:491\u20136.","journal-title":"Ann Surg Oncol."},{"key":"20254_CR5","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1007\/s00384-021-04012-7","volume":"36","author":"R van der Meer","year":"2021","unstructured":"van der Meer R, Bakkers C, Rostamkhan E, de Hingh I, Roumen R. Ovarian metastases from colorectal cancer in young women: a systematic review of the literature. Int J Colorectal Dis. 2021;36:2567\u201375.","journal-title":"Int J Colorectal Dis."},{"key":"20254_CR6","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1097\/DCR.0000000000000791","volume":"60","author":"AM Mehta","year":"2017","unstructured":"Mehta AM, Bignell MB, Alves S, et al. Risk of ovarian involvement in advanced colorectal or appendiceal tumors involving the peritoneum. Dis Colon Rectum. 2017;60:691\u20136.","journal-title":"Dis Colon Rectum."},{"key":"20254_CR7","doi-asserted-by":"publisher","first-page":"1485694","DOI":"10.3389\/fonc.2025.1485694","volume":"15","author":"F Fu","year":"2025","unstructured":"Fu F, Ma X, Weng Z, Lu Y, Xu H, Ma R. Prophylactic oophorectomy is recommended in female patients with pseudomyxoma peritonei of an appendiceal origin. Front Oncol. 2025;15:1485694.","journal-title":"Front Oncol."},{"key":"20254_CR8","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/codi.14057","volume":"20","author":"MB Bignell","year":"2018","unstructured":"Bignell MB, Mehta AM, Alves S, et al. Impact of ovarian metastases on survival in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancy originating from appendiceal and colorectal cancer. Colorectal Dis. 2018;20:704\u201310.","journal-title":"Colorectal Dis."},{"key":"20254_CR9","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1245\/s10434-024-16116-9","volume":"32","author":"NM Winicki","year":"2025","unstructured":"Winicki NM, Radomski SN, Florissi IS, et al. Management of the uninvolved uterus and adnexa during routine pelvic peritonectomy in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy varies by histology and menopausal status: an international survey of peritoneal surface malignancy surgeons. Ann Surg Oncol. 2025;32:671\u20138.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"20254_CR10","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1245\/s10434-025-18421-3","volume":"3","author":"P Marincola Smith","year":"2025","unstructured":"Marincola Smith P, Lie JJ, Seldomridge A, et al. Repeat cytoreductive surgery for colorectal cancer metastatic to the peritoneal cavity. Ann Surg Oncol. 2025;3(3):1952\u201364.","journal-title":"Ann Surg Oncol."},{"key":"20254_CR11","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1200\/JCO.2018.78.1914","volume":"36","author":"K Oktay","year":"2018","unstructured":"Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36:1994\u20132001.","journal-title":"J Clin Oncol."},{"key":"20254_CR12","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/PPO.0b013e3181a9c6f0","volume":"15","author":"P Bao","year":"2009","unstructured":"Bao P, Bartlett D. Surgical techniques in visceral resection and peritonectomy procedures. Cancer J. 2009;15:204\u201311.","journal-title":"Cancer J."},{"key":"20254_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/jso.21388","volume":"100","author":"M Deraco","year":"2009","unstructured":"Deraco M, Baratti D, Kusamura S, Laterza B, Balestra MR. Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. J Surg Oncol. 2009;100:321\u20138.","journal-title":"J Surg Oncol."},{"key":"20254_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1515\/pp-2020-0149","volume":"6","author":"M Larroque","year":"2021","unstructured":"Larroque M, Mounicou S, Sgarbura O, et al. Study of oxaliplatin penetration into ovaries of patients treated with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastases of colorectal and appendiceal origin using mass spectrometry imaging. Pleura Peritoneum. 2021;6:67\u201374.","journal-title":"Pleura Peritoneum."},{"key":"20254_CR15","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1080\/01443615.2022.2055453","volume":"42","author":"D Papageorgiou","year":"2022","unstructured":"Papageorgiou D, Diakosavvas M, Angelou K, et al. Fertility outcomes after treatment with intraperitoneal chemotherapy. J Obstet Gynaecol. 2022;42:1626\u201334.","journal-title":"J Obstet Gynaecol."},{"key":"20254_CR16","first-page":"163","volume":"12","author":"A Cercek","year":"2013","unstructured":"Cercek A, Siegel CL, Capanu M, Reidy-Lagunes D, Saltz LB. Incidence of chemotherapy-induced amenorrhea in premenopausal women treated with adjuvant FOLFOX for colorectal cancer. Clin Colorectal Cancer. 2013;12:163\u20137.","journal-title":"Clin Colorectal Cancer."},{"key":"20254_CR17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/BF02237479","volume":"41","author":"TM Young-Fadok","year":"1998","unstructured":"Young-Fadok TM, Wolff BG, Nivatvongs S, Metzger PP, Ilstrup DM. Prophylactic oophorectomy in colorectal carcinoma: preliminary results of a randomized, prospective trial. Dis Colon Rectum. 1998;41:277\u201383.","journal-title":"Dis Colon Rectum."},{"key":"20254_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.5306\/wjco.v9.i1.13","volume":"9","author":"I Seow-En","year":"2018","unstructured":"Seow-En I, Hwarng G, Tan GHC, Ho LML, Teo MCC. Palliative surgery for Krukenberg tumors: 12-year experience and review of the literature. World J Clin Oncol. 2018;9:13\u20139.","journal-title":"World J Clin Oncol."},{"key":"20254_CR19","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12957-021-02305-3","volume":"19","author":"C Chen","year":"2021","unstructured":"Chen C, Wang D, Ge X, et al. Prognostic factors for ovarian metastases in colorectal cancer patients. World J Surg Oncol. 2021;19:220.","journal-title":"World J Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20254-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20254-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20254-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:06:44Z","timestamp":1784225204000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20254-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":19,"alternative-id":["20254"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20254-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"26 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"John-Paul Shen received grant\/research support\/collaboration from Natera, Inc, BostonGene, Revolution Medicine, and Summit Therapeutics; consulting\/stock ownership from Engine Biosciences and NaDeNo Nanoscience. J. Joshua Smith received travel support for fellow education from Intuitive Surgical (August 2015). Dr. Smith served as a clinical advisor for Guardant Health (March 2019), as a clinical advisor for Foundation Medicine (April 2022), as a consultant and speaker for Johnson and Johnson (May 2022), as a clinical advisor for Urogen (January 2025), as a clinical advisor for Regeneron (January 2025), as a clinical advisor and consultant for GSK (2023\u20132025) and SK (2023\u20132025), as a clinical consultant for Gerson Lehrman Group (March 2025), as a clinical consultant for BioNTech (May 2025), and as a clinical consultant for Clario (2025\u20132026).","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}